Please upgrade your browser.
Transitional cell cancer is a cancer occurring in the urinary system, i.e., the kidneys, urinary bladder and accessory organs of the urinary system and occurs in the inner tissue lining of these hollow organs.
Health information technology (health IT) makes it possible for health care providers to better manage patient care through secure use and sharing of health information.
Get a maximum tax deduction and join the fight against kidney cancer by donating your old vehicle to the Kidney Cancer Association.
Rintatolimod was first synthesized in the 1970s and has been proposed as a treatment for illnesses such as CFS, HIV, hepatitis B, hepatitis C, and cancers, including renal cell cancer...
Meeting agenda and related materials, including abstract previews
Will this happen to patients living with kidney cancer under ObamaCare? Roy Dashwood, 81, who has advanced kidney cancer, will have to pay for all his treatments, test and travel, out of pocket, if he takes a new drug recommended by his oncologist.
Curis, Inc. (CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Patent and Trademark Office has issued a patent covering a genus of compounds that includes Debio 0932, an orally-administered Heat Shock Protein 90 (HSP90) inhibitor, which is being developed by Curis' licensee Debiopharm.
Ottawa's Funhaven Family Fun Centre threw a party for 6-year-old Isaac Ciarlo and more than 100 of his family and friends to celebrate the end of the young boy's cancer treatments.
NICE, the healthcare guidance body, has issued draft guidance not recommending axitinib (Inlyta, Pfizer) for the treatment of advanced kidney cancer. When IPAB convenes under ObamaCare, patients in the US should beware that their drug access may be severely limited, as is now the case in the UK.
Will "ObamaCare" result in a poorer standard of care for those dealing with renal cancers? Some observers believe the US House of Representatives could still prevail in gutting or repealing ACA, due to massive cost overruns that might result in the unseating of Senate Democrats. "Obamacare" remains overwhelmingly unpopular with the public, including with many of those who voted for the president.
|Powered by NeonCRM|